Showing 3181-3190 of 6035 results for "".
- Lens Replacement Because of Cataracts May Improve Sleephttps://modernod.com/news/lens-replacement-because-of-cataracts-may-improve-sleep/2476610/Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates the body’s internal clock, according to a Reuters
- Study Probes ODs’ Attitudes About Blue-Light Blocking Deviceshttps://modernod.com/news/study-probes-ods-attitudes-about-blue-light-blocking-devices/2476599/A recent study found that optometrists remain split on the impact of blue light from electronic devices, such as computer and phone screens, and the effectiveness of blue light-blocking devices, according to reporting by Patrick Campbell in MD Magazine, as
- Evaluation of a Remote Diagnosis Imaging Model vs Dilated Eye Examination in Referable Macular Degenerationhttps://modernod.com/news/evaluation-of-a-remote-diagnosis-imaging-model-vs-dilated-eye-examination-in-referable-macular-degeneration/2476596/Researchers examined if the identification of referable macular degeneration could be done using the remote diagnosis imaging model as a clinical screening tool. They conducted a nonrandomized study of 159 patients in facilities with high rates of diabetic retinopathy and age-related macular dege
- Dexamethasone Injection May Speed IOP Drop in Angle-Closure Glaucomahttps://modernod.com/news/dexamethasone-injection-may-speed-iop-drop-in-angle-closure-glaucoma/2476594/In acute primary angle closure (APAC), subconjunctival dexamethasone injection helps high IOP drop more quickly and improves treatment success rate, researchers in China report, according to a Reuters report. “The anti-inflam
- Second Sight to Accelerate Development of Orion Visual Cortical Prosthesis Systemhttps://modernod.com/news/second-sight-to-accelerate-development-of-orion-visual-cortical-prosthesis-system/2476589/Second Sight Medical Products announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System. Orion holds the potential to provide useful artificial vision to individuals blind from many causes, including glaucoma, eye injury, diabetic retino
- MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiencyhttps://modernod.com/news/meiragtx-announces-positive-6-month-data-from-phase-1-2-trial-of-investigational-gene-therapy-aav-rpe65-for-rpe65-deficiency/2476582/MeiraGTx Holdings announced positive data from a phase 1/2 dose escalation trial of AAV-RPE65, the company’s investigational gene therapy for the treatment of RPE65-deficiency, a condition that causes blindness. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to tre
- Novartis to Acquire Dry Eye Drug Xiidra in Deal Worth Up to $5.3 Billionhttps://modernod.com/news/novartis-to-acquire-dry-eye-drug-xiidra-in-deal-worth-up-to-5-3-billion/2476567/In one of the largest ophthalmic drug deals to date, Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda Pharmaceutical in a deal worth up to $5.3 billion. Under terms of the deal, Novartis will pay $3.4 billi
- Genentech: Pivotal Phase 3 Data for Neuromyelitis Optica Spectrum Disorder (Devic’s Disease)https://modernod.com/news/genentech-pivotal-phase-3-data-for-neuromyelitis-optica-spectrum-disorder-devics-disease/2476566/Genentech presented new pivotal phase 3 data for the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), also known as Devic’s Disease, for which there are no approved treatments. NMOSD is a rare, lifelong and debilitating autoimmune disease of the c
- Preclinical Studies Demonstrate Galimedix’s GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Modelshttps://modernod.com/news/preclinical-studies-demonstrate-galimedixs-gal-101-shows-neuroprotective-effect-from-toxic-amyloid-beta-in-dry-amd-and-glaucoma-models/2476564/Galimedix Therapeutics presented data demonstrating its novel, first-in-class, investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. Further, investiga
- The Healthcare Alliance for Patient Safety Statement in Response to FTC Proposed Contact Lens Rulehttps://modernod.com/news/the-healthcare-alliance-for-patient-safety-statement-in-response-to-ftc-proposed-contact-lens-rule/2476553/The Healthcare Alliance for Patient Safety (Alliance) released the following statement in response to last week’s Federal Trade Commission (FTC) proposed supplemental rulemaking on the 2016 proposed Contact Lens Rule. Congress charged the FTC with enforcing contact lens prescription